These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Pharmacogenetics begins to deliver on its promises. Li-Wan-Po A BMJ; 2015 Sep; 351():h5042. PubMed ID: 26400246 [No Abstract] [Full Text] [Related]
33. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study. Lin CW; Huang WI; Chao PH; Chen WW; Hsiao FY Int J Clin Pract; 2019 May; 73(5):e13316. PubMed ID: 30681751 [TBL] [Abstract][Full Text] [Related]
34. Allopurinol--dose according to effect, not renal function. Bryant L J Prim Health Care; 2011 Dec; 3(4):323. PubMed ID: 22235497 [No Abstract] [Full Text] [Related]
35. Hypothyroidism on Colchimax revealed by restless legs syndrome. Bon E; Rolland Y; Laroche M; Cantagrel A; Mazières B Rev Rhum Engl Ed; 1996 Apr; 63(4):304. PubMed ID: 8738454 [No Abstract] [Full Text] [Related]
36. Treatment of gout in a renal transplant patient leading to severe thrombocytopenia. Weiler S; Aellig N; Fauchère I; Jetter A; Corti N J Clin Pharm Ther; 2014 Oct; 39(5):571-2. PubMed ID: 25040676 [TBL] [Abstract][Full Text] [Related]
37. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia. Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593 [No Abstract] [Full Text] [Related]
38. Chronic tophaceous gout in a patient with a history of allopurinol toxicity. Naas JE; Sanders LJ Cutis; 1998 Nov; 62(5):239-41. PubMed ID: 9836057 [TBL] [Abstract][Full Text] [Related]